These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 15968396

  • 1. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.
    Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM.
    Thromb Haemost; 2005 Jun; 93(6):1108-16. PubMed ID: 15968396
    [Abstract] [Full Text] [Related]

  • 2. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
    Pradhan AD, LaCroix AZ, Langer RD, Trevisan M, Lewis CE, Hsia JA, Oberman A, Kotchen JM, Ridker PM.
    Circulation; 2004 Jul 20; 110(3):292-300. PubMed ID: 15238458
    [Abstract] [Full Text] [Related]

  • 3. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.
    Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM.
    JAMA; 2002 Aug 28; 288(8):980-7. PubMed ID: 12190368
    [Abstract] [Full Text] [Related]

  • 4. Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic american Indian women: the strong heart study.
    Zhang Y, Howard BV, Cowan LD, Welty TK, Schaefer CF, Wild RA, Yeh J, Lee ET.
    J Womens Health (Larchmt); 2004 Mar 28; 13(2):155-63. PubMed ID: 15072729
    [Abstract] [Full Text] [Related]

  • 5. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy.
    Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, Pettinger M, Robinson J, Hendrix S, Hsia J.
    Arch Intern Med; 2008 Nov 10; 168(20):2245-53. PubMed ID: 19001202
    [Abstract] [Full Text] [Related]

  • 6. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women.
    Everett BM, Kurth T, Buring JE, Ridker PM.
    J Am Coll Cardiol; 2006 Dec 05; 48(11):2235-42. PubMed ID: 17161253
    [Abstract] [Full Text] [Related]

  • 7. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K, Neuenschwander PF, Kurdowska AK.
    Int J Pharm Compd; 2013 Dec 05; 17(1):74-85. PubMed ID: 23627249
    [Abstract] [Full Text] [Related]

  • 8. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H.
    Thromb Haemost; 2001 Apr 05; 85(4):619-25. PubMed ID: 11341495
    [Abstract] [Full Text] [Related]

  • 9. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines.
    Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J.
    Circulation; 2004 Nov 02; 110(18):2824-30. PubMed ID: 15492318
    [Abstract] [Full Text] [Related]

  • 10. Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study.
    May M, Lawlor DA, Patel R, Rumley A, Lowe G, Ebrahim S.
    Eur J Cardiovasc Prev Rehabil; 2007 Oct 02; 14(5):638-45. PubMed ID: 17925622
    [Abstract] [Full Text] [Related]

  • 11. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Oct 02; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 12. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
    Straczek C, Tafflet M, Barberger-Gateau P, Bertrand M, Dupuy AM, Ducimetière P, Empana JP.
    Atherosclerosis; 2011 Feb 02; 214(2):426-31. PubMed ID: 21129746
    [Abstract] [Full Text] [Related]

  • 13. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
    Ridker PM, Hennekens CH, Buring JE, Rifai N.
    N Engl J Med; 2000 Mar 23; 342(12):836-43. PubMed ID: 10733371
    [Abstract] [Full Text] [Related]

  • 14. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG, Herrington DM.
    Climacteric; 2005 Dec 23; 8(4):317-26. PubMed ID: 16390766
    [Abstract] [Full Text] [Related]

  • 15. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events.
    Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, Margolis KL, Women's Health Initiative Investigators.
    Am J Cardiol; 2008 Jun 01; 101(11):1599-1605. PubMed ID: 18489937
    [Abstract] [Full Text] [Related]

  • 16. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study.
    Kaplan RC, McGinn AP, Baird AE, Hendrix SL, Kooperberg C, Lynch J, Rosenbaum DM, Johnson KC, Strickler HD, Wassertheil-Smoller S.
    J Stroke Cerebrovasc Dis; 2008 Jun 01; 17(6):344-55. PubMed ID: 18984425
    [Abstract] [Full Text] [Related]

  • 17. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).
    Shlipak MG, Chaput LA, Vittinghoff E, Lin F, Bittner V, Knopp RH, Hulley SB, Heart and Estrogen/progestin Replacement Study Investigators.
    Am Heart J; 2003 Nov 01; 146(5):870-5. PubMed ID: 14597937
    [Abstract] [Full Text] [Related]

  • 18. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators.
    N Engl J Med; 2003 Aug 07; 349(6):523-34. PubMed ID: 12904517
    [Abstract] [Full Text] [Related]

  • 19. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).
    Simon JA, Lin F, Vittinghoff E, Bittner V, Heart and Estrogen-Progestin Replacement Study (HERS) Research Group.
    Ann Epidemiol; 2006 Feb 07; 16(2):138-45. PubMed ID: 16039873
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease.
    Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G.
    J Thromb Haemost; 2007 Sep 07; 5(9):1795-800. PubMed ID: 17723116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.